People who received POLIVY+BR had a complete remission or a partial remission more often compared with those who received BR by itself.
63% of the people who received POLIVY+BR had a complete or partial remission at some point in the study (25 out of 40), compared with 25% of those who received BR by itself (10 out of 40).
*Doctors in the study checked response to treatment 6 to 8 weeks after Day 1 of cycle 6 or last study treatment.
Of the 10 people who responded to BR treatment by itself, 20% had a DoR of at least 12 months (2 out of 10), and 30% had a DoR of at least 6 months (3 out of 10).
Duration of response (DoR) is the length of time a person is in remission, from where they first respond to treatment to when the disease gets worse. DoR includes people who have had a complete remission or partial remission at any time in the study.
POLIVY plus a chemotherapy regimen of bendamustine and a rituximab product (POLIVY+BR) was compared with BR by itself in a clinical trial. It was studied in 80 patients with R/R DLBCL.
Patients received either POLIVY+BR or BR by itself every 21 days for 6 treatment cycles. Both patients and healthcare providers knew which treatment had been given.
Patients in the study were randomized (or sorted) by the length of time they responded to a previous treatment (also known as duration of response, or DoR).
The study included patients with R/R DLBCL who:
The study did not include people
HSCT=hematopoietic stem cell transplantation.
*Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which cancer cells from other parts of the body form in the brain and/or spinal cord.
†Transformed lymphoma occurs when a slow-growing lymphoma develops into a more aggressive one.
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.